CL-SBP-101-03
07 Dec 2020
Trial Summary
A Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma Previously Untreated Metastatic Pancreatic Ductal Adenocarcin
Acronym:
CL-SBP-101-03
ACTRN/NCT /ethics:
NCT03412799
Scientific title:
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Sponsor / Cooperative group:
Sun BioPharma Inc
Trial & Patient Characteristics
| Cancer Type | Pancreas |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-06-04 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruiting |